Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 5
- 主要终点
- Change From Baseline Menses for Participant Perceived Blood Loss
研究概览
简要总结
This is a study to learn more about a drug called Tranexamic acid (TA), otherwise known as Lysteda, and whether or not this drug can decrease menstrual blood loss in young women and lead to an increase in the quality of life.
Menorrhagia in young women with bleeding disorders is typically treated with a combination of treatments including hormonal contraceptives. However, there are barriers to hormonal contraception use in younger adolescents.
Tranexamic acid is taken orally during the first 5 days of menstrual bleeding.
The purposes of this study include:
To test the safety and efficacy of Lysteda in adolescent females. To learn how well Lysteda works in decreasing menstrual blood loss. To see if parents and children participating in this study think the drug is improving their quality of life.
Lysteda has been approved by the Food and Drug Administration for use in patients > than 18 years of age but not for younger patients.
详细描述
This is a multi-center (5 sites) open-label, single-arm, efficacy study of Lysteda in the treatment of adolescent females (10-19 years of age) with heavy menstrual bleeding (HMB). Each subject will receive oral Lysteda 1.3 grams three times daily during the first five days of menses. Subjects will be monitored over the course of four menstrual cycles (1 pre-treatment cycle and 3 treatment cycles). During all cycles, assessments of menstrual bleeding will be performed using the Menorrhagia Impact Questionnaire (MIQ) and Pictorial Blood Assessment Chart (PBAC).
The study will begin as a currently funded pilot study to assess the efficacy of Lysteda in 32 patients followed to study completion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 10 Years 至 19 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Menstruating females 10-19 years of age
- •Physician and patient have agreed to initiate Lysteda
- •Diagnosis of HMB based on the medical judgment of the principal or site investigator
- •Subjects must report menstrual periods occurring within 21-60 days from the start of one period to the start of the next menstrual period
- •Negative pregnancy test
- •Informed consent obtained and signed
- •Informed assent obtained and signed
- •Understanding of study procedures
- •Ability to comply with study procedures for the entire length of the study
- •Subjects should be either sexually inactive (abstinent) or agree to use a barrier method with spermicide in the event of sexual activity throughout the study period
排除标准
- •Active thromboembolic disease, history of thromboembolic disease (including retinal vein or artery occlusion), known inherited thrombophilia, or family history of thrombosis in a first degree relative
- •Subject has a severe medical or psychiatric illness that, in the opinion of the Investigator, would affect subject safety or compliance
- •Clinical evidence of severe bleeding disorder. Patients with mild bleeding disorders such as type 1 von Willebrand disease, mild platelet function defects such as platelet storage pool or release defects, and patients with bleeding due to Ehlers Danlos syndrome WILL be eligible to participate in the study.
- •Pregnancy within the past 6 months and/or breast-feeding
- •Use of hormonal contraception (estrogen and progestin) within 3 months of study entry, or anticipated need to initiate estrogen-containing hormonal contraception during the study period
- •Use of systemic steroids within 1 month of study entry
- •History of subarachnoid hemorrhage
- •History of Hepatitis B, C, or HIV
- •Baseline creatinine >20% above the upper limit of normal for age
- •Severe anemia (hemoglobin <8 g/dL)
- •Systolic blood pressure <85 or diastolic blood pressure <55
- •Heart rate <50 at time of screening
- •Use of intranasal DDAVP during menses will be permitted, but only if the patient has a history of using DDAVP consistently for ≥3 menstrual cycles prior to study enrollment, so that change in menstrual blood loss due to addition of Lysteda can be assessed. Use of one-time DDAVP during a DDAVP/Stimate challenge is also permitted during the study period, as is use of DDAVP in the event of severe epistaxis, trauma, or surgical procedures during the study period.
研究组 & 干预措施
Tranexamic acid
Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
干预措施: Tranexamic Acid (Drug)
结局指标
主要结局
Change From Baseline Menses for Participant Perceived Blood Loss
时间窗: Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid
Menorrhagia Impact Questionnaire (MIQ): Question 1 - participant perceived blood loss during most recent menses. Scale ranges from a score of 1 to 4 (with 1 being light blood loss and 4 being very heavy blood loss). Lower values indicate a better outcome (less blood loss during menses). Unit of measure is scores on a scale.
次要结局
- Change From Baseline Menses for Ferritin Lab Value(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
- Change From Baseline Menses for Hemoglobin Lab Value(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
- Change From Baseline Menses for Participant Perceived Limitation of School Attendance(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
- Change From Baseline Menses for Participant Perceived Limitation of Social or Leisure Activities(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
- Change From Baseline Menses for Participant Perceived Limitation in Physical Activities(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
- Change From Baseline Menses for Menstrual Blood Loss as Measured by Pictorial Blood Assessment Chart (PBAC) Scores(Baseline menses (no treatment) and 3 menstrual cycles treated with tranexamic acid)
研究者
Sarah O'Brien
Director of Experimental Therapeutics
Nationwide Children's Hospital